Clinical Trial Update: Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing lenvatinib as a conversion therapy for hepatocellular carcinoma (HCC) with efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: UNKNOWN